Dutasteride for Hair Loss: Stronger Than Finasteride, and Off-Label

Finasteride is the drug approved for hair loss. Dutasteride is the drug that works slightly better and is not approved for hair loss anywhere in the United States. That gap between efficacy and regulatory status is most of what a man needs to understand before deciding whether to take it, and it is the part clinics selling it tend to skip.

The two enzymes

Male pattern hair loss is driven by dihydrotestosterone acting on genetically susceptible follicles. DHT is made from testosterone by an enzyme called 5-alpha reductase, which exists in two forms. Type II predominates in hair follicles and the prostate. Type I is more prominent in sebaceous glands, skin and liver, and it contributes too.

Finasteride, per its FDA label, is a competitive and specific inhibitor of type II. Dutasteride inhibits both type I and type II. That single structural difference drives everything else.

All four rows come from the drugs’ own FDA prescribing information, which is the most defensible source available. You will see other numbers quoted, often 98 percent against 71 percent, drawn from a 2004 pharmacology study. The direction is the same; the labels are the figures worth relying on.

The head-to-head trial

One trial has compared them properly. It randomised 917 men aged 20 to 50 to dutasteride at 0.02, 0.1 or 0.5 mg daily, finasteride 1 mg daily, or placebo, for 24 weeks, with hair count in a 2.54 cm target area as the primary endpoint.

Dutasteride produced dose-dependent increases in both hair count and hair width. At 0.5 mg it beat finasteride 1 mg on hair count (P = .003), hair width (P = .004), and blinded panel assessment of photographs (P = .002). Against placebo, everything reached P < .001. The number and severity of adverse events were similar across groups.

The absolute changes, as tabulated in a later review, were an increase of 17.68 hairs per square centimetre on dutasteride 0.5 mg, 11.15 on finasteride 1 mg, and a loss of 0.97 on placebo.

Two limitations the authors themselves flag. The trial ran 24 weeks, which is short for a condition treated over decades, and the comparison is at a single timepoint. Hair count differences at six months do not automatically hold at two years.

Where it sits among all the options

A network meta-analysis published in JAMA Dermatology in 2022 ranked the treatments against each other. At 24 weeks, dutasteride 0.5 mg daily produced the greatest increase in total hair count of anything assessed.

The 7.1 figure is worth holding onto because it arrives independently of the head-to-head trial and lands close to the difference that trial implies. Two separate methods agreeing is more persuasive than either alone.

The caveat is the same one: this ranking is at 24 weeks. At 48 weeks the same analysis found finasteride at 5 mg and 1 mg superior to topical minoxidil formulations, but it did not establish a 48-week dutasteride-versus-finasteride result. Anyone presenting dutasteride’s superiority as a settled long-term fact is going beyond the data.

A real-world comparison offers a different angle. A multicentre chart review of 600 South Korean patients found that among men with the basic male pattern, 86.0 percent improved on dutasteride against 45.5 percent on finasteride, an adjusted incidence rate ratio of 2.06 (1.08 to 3.95, P = 0.029). Chart reviews are not trials and cannot control for why a given man was put on a given drug, but the direction is consistent.

What it is actually approved for

This is where most articles get vague, so here is the precise position.

In the United States, dutasteride is approved to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate, and for nothing else. Its label states in plain words that it is not approved for the prevention of prostate cancer. Initial US approval was in 2001. It has no FDA approval for androgenetic alopecia, so every American prescription for hair loss is off-label.

Off-label is legal, common, and not by itself a red flag. It does mean the FDA has never reviewed dutasteride’s efficacy or safety for this use at this dose in this population, and that the prescriber is carrying that judgment personally.

Elsewhere it is approved for hair loss. South Korea approved it for androgenetic alopecia in 2009. Japan approved it in 2015, marketed as Zagallo, with the indication stated as androgenetic alopecia in men.

For contrast, finasteride 1 mg has been approved for male pattern hair loss in men only since the 1990s, which is why it is the default and why the safety database behind it is far larger.

Side effects, honestly

The two drugs’ labels report sexual adverse effects at these rates, though note these are from prostate and hair-loss trial populations respectively and are not directly comparable.

Do not read the left column as showing dutasteride is worse. Those figures come from men with enlarged prostates, who are older and have more baseline sexual dysfunction than the men in hair-loss trials. When the comparison is made within the same population the picture flips or flattens.

In the 24-week head-to-head trial, adverse event rates were 10.3 to 12.8 percent on dutasteride, 13.4 percent on finasteride, and 6.6 percent on placebo. In the 600-patient Korean chart review, overall adverse events were 7.6 percent on dutasteride against 10.5 percent on finasteride, with sexual adverse events at 1.6 percent and 1.1 percent respectively.

A meta-analysis of relative risk against placebo found finasteride 1 mg carried a 1.66-fold risk of sexual adverse effects (1.20 to 2.30), which is statistically significant, while dutasteride 0.5 mg came in at 1.37 (0.81 to 2.32), which is not. The honest reading of all of this is that the two drugs’ side effect profiles are closer than their potency difference would suggest, and that neither is clearly worse.

On persistence after stopping, both labels acknowledge it and neither establishes causation. The dutasteride label states that sexual adverse reactions may persist after discontinuation and that the role of dutasteride in that persistence is unknown. The finasteride label lists persistent sexual dysfunction in its postmarketing section, while its clinical trial section reports that resolution occurred in men who discontinued and in most who continued, with incidence falling to 0.3 percent or below by the fifth year of treatment. Those two statements sit in the same document and the tension between them is real rather than a drafting error.

The PSA problem

This is the most clinically important thing on the page and the least discussed.

Both drugs roughly halve PSA. Dutasteride’s label states it reduces serum PSA by approximately 50 percent within three to six months, and instructs that to interpret an isolated PSA in a man treated for three months or more, the value should be doubled before comparing it with normal ranges. Finasteride at 5 mg carries the same instruction. Finasteride at 1 mg lowers PSA too: in men aged 18 to 41 the label reports a fall from 0.7 to 0.5 ng/mL over twelve months.

The practical consequence is blunt. A man taking either drug who does not tell the doctor ordering his PSA can receive a falsely reassuring result. A reading of 3.0 that should have been read as 6.0 is the difference between routine follow-up and referral.

The labels also give the more useful monitoring rule: establish a new PSA baseline at least three months after starting, then treat any confirmed increase from the lowest on-drug value as a signal worth evaluating, even if the number is still inside the normal range. The trend matters more than the threshold.

There is a second, more contested issue. In the trials of both drugs for prostate purposes, high-grade cancers were slightly more common in the treated groups. In the dutasteride trial, Gleason 8 to 10 cancers occurred in 1.0 percent against 0.5 percent on placebo. In the finasteride prevention trial, 1.8 percent against 1.1 percent. Whether this reflects genuine induction of aggressive disease or an artefact of smaller prostates making cancers easier to find has been argued for two decades without resolution. Both figures come from older men taking these drugs for prostate indications, not from young men taking them for hair, and no comparable signal has been reported in the hair-loss population. It belongs in the conversation, not at the centre of it.

Half-life, blood donation, stopping

Dutasteride’s five-week half-life is the practical difference that men underestimate. Serum concentrations remain detectable for up to four to six months after the last dose. If the drug suits you, that is forgiving of a missed day. If it does not, you cannot simply stop and be clear of it next week.

That same persistence drives the donation rule. The label instructs that men treated with dutasteride should not donate blood until at least six months have passed since their last dose, because a transfusion to a pregnant woman could expose a male fetus.

The pregnancy warnings are not boilerplate. Dutasteride capsules should not be handled by women who are pregnant or may become pregnant, because the drug is absorbed through skin. Finasteride carries a comparable warning about crushed or broken tablets, on the basis that it can cause abnormalities of the external genitalia of a male fetus. A leaking capsule left on a bathroom shelf is a genuine, if small, household hazard.

On stopping: whatever either drug gained is lost. The finasteride label states that withdrawal of treatment leads to reversal of effect within twelve months. These are maintenance drugs, not courses, and a man who is not prepared to take something indefinitely is better served by knowing that before he starts than by discovering it a year after he stops.

One final note on the injectable version. Dutasteride delivered into the scalp, sold as mesotherapy, is marketed as a way to get the benefit without systemic exposure. The evidence is thin: a small, heterogeneous literature with injection schedules ranging from weekly to monthly, mostly non-randomised, and systematically confounded because the injected solutions typically also contain biotin and D-panthenol. In one review’s tabulation, dutasteride alone produced photographic improvement in about 30 percent of patients against 17.5 to 30 percent for saline, which is barely a separation. Paradoxical hair loss has been reported as a complication. It is not a settled alternative to taking the tablet.

This article is for information only and is not medical advice. Dutasteride is a prescription medicine and is not approved in the United States for hair loss. Tell any doctor ordering a PSA test that you are taking a 5-alpha reductase inhibitor.